Cargando…

Decreased cerebrospinal fluid orexin levels not associated with clinical sleep disturbance in Parkinson’s disease: A retrospective study

Patients with Parkinson’s disease (PD) often suffer from sleep disturbances, including excessive daytime sleepiness (EDS) and rapid eye movement sleep behavior disorder (RBD). These symptoms are also experienced by patients with narcolepsy, which is characterized by orexin neuronal loss. In PD, a de...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogawa, Takuya, Kajiyama, Yuta, Ishido, Hideaki, Chiba, Shigeru, Revankar, Gajanan S., Nakano, Tomohito, Taniguchi, Seira, Kanbayashi, Takashi, Ikenaka, Kensuke, Mochizuki, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803214/
https://www.ncbi.nlm.nih.gov/pubmed/36584130
http://dx.doi.org/10.1371/journal.pone.0279747
_version_ 1784861832604811264
author Ogawa, Takuya
Kajiyama, Yuta
Ishido, Hideaki
Chiba, Shigeru
Revankar, Gajanan S.
Nakano, Tomohito
Taniguchi, Seira
Kanbayashi, Takashi
Ikenaka, Kensuke
Mochizuki, Hideki
author_facet Ogawa, Takuya
Kajiyama, Yuta
Ishido, Hideaki
Chiba, Shigeru
Revankar, Gajanan S.
Nakano, Tomohito
Taniguchi, Seira
Kanbayashi, Takashi
Ikenaka, Kensuke
Mochizuki, Hideki
author_sort Ogawa, Takuya
collection PubMed
description Patients with Parkinson’s disease (PD) often suffer from sleep disturbances, including excessive daytime sleepiness (EDS) and rapid eye movement sleep behavior disorder (RBD). These symptoms are also experienced by patients with narcolepsy, which is characterized by orexin neuronal loss. In PD, a decrease in orexin neurons is observed pathologically, but the association between sleep disturbance in PD and cerebrospinal fluid (CSF) orexin levels is still unclear. This study aimed to clarify the role of orexin as a biomarker in patients with PD. CSF samples were obtained from a previous cohort study conducted between 2015 and 2020. We cross-sectionally and longitudinally examined the association between CSF orexin levels, sleep, and clinical characteristics. We analyzed 78 CSF samples from 58 patients with PD and 21 samples from controls. CSF orexin levels in patients with PD (median = 272.0 [interquartile range = 221.7–334.5] pg/mL) were lower than those in controls (352.2 [296.2–399.5] pg/mL, p = 0.007). There were no significant differences in CSF orexin levels according to EDS, RBD, or the use of dopamine agonists. Moreover, no significant correlation was observed between CSF orexin levels and clinical characteristics by multiple linear regression analysis. Furthermore, the longitudinal changes in orexin levels were also not correlated with clinical characteristics. This study showed decreased CSF orexin levels in patients with PD, but these levels did not show any correlation with any clinical characteristics. Our results suggest the limited efficacy of CSF orexin levels as a biomarker for PD, and that sleep disturbances may also be affected by dysfunction of the nervous system other than orexin, or by dopaminergic treatments in PD. Understanding the reciprocal role of orexin among other neurotransmitters may provide a better treatment strategy for sleep disturbance in patients with PD.
format Online
Article
Text
id pubmed-9803214
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-98032142022-12-31 Decreased cerebrospinal fluid orexin levels not associated with clinical sleep disturbance in Parkinson’s disease: A retrospective study Ogawa, Takuya Kajiyama, Yuta Ishido, Hideaki Chiba, Shigeru Revankar, Gajanan S. Nakano, Tomohito Taniguchi, Seira Kanbayashi, Takashi Ikenaka, Kensuke Mochizuki, Hideki PLoS One Research Article Patients with Parkinson’s disease (PD) often suffer from sleep disturbances, including excessive daytime sleepiness (EDS) and rapid eye movement sleep behavior disorder (RBD). These symptoms are also experienced by patients with narcolepsy, which is characterized by orexin neuronal loss. In PD, a decrease in orexin neurons is observed pathologically, but the association between sleep disturbance in PD and cerebrospinal fluid (CSF) orexin levels is still unclear. This study aimed to clarify the role of orexin as a biomarker in patients with PD. CSF samples were obtained from a previous cohort study conducted between 2015 and 2020. We cross-sectionally and longitudinally examined the association between CSF orexin levels, sleep, and clinical characteristics. We analyzed 78 CSF samples from 58 patients with PD and 21 samples from controls. CSF orexin levels in patients with PD (median = 272.0 [interquartile range = 221.7–334.5] pg/mL) were lower than those in controls (352.2 [296.2–399.5] pg/mL, p = 0.007). There were no significant differences in CSF orexin levels according to EDS, RBD, or the use of dopamine agonists. Moreover, no significant correlation was observed between CSF orexin levels and clinical characteristics by multiple linear regression analysis. Furthermore, the longitudinal changes in orexin levels were also not correlated with clinical characteristics. This study showed decreased CSF orexin levels in patients with PD, but these levels did not show any correlation with any clinical characteristics. Our results suggest the limited efficacy of CSF orexin levels as a biomarker for PD, and that sleep disturbances may also be affected by dysfunction of the nervous system other than orexin, or by dopaminergic treatments in PD. Understanding the reciprocal role of orexin among other neurotransmitters may provide a better treatment strategy for sleep disturbance in patients with PD. Public Library of Science 2022-12-30 /pmc/articles/PMC9803214/ /pubmed/36584130 http://dx.doi.org/10.1371/journal.pone.0279747 Text en © 2022 Ogawa et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Ogawa, Takuya
Kajiyama, Yuta
Ishido, Hideaki
Chiba, Shigeru
Revankar, Gajanan S.
Nakano, Tomohito
Taniguchi, Seira
Kanbayashi, Takashi
Ikenaka, Kensuke
Mochizuki, Hideki
Decreased cerebrospinal fluid orexin levels not associated with clinical sleep disturbance in Parkinson’s disease: A retrospective study
title Decreased cerebrospinal fluid orexin levels not associated with clinical sleep disturbance in Parkinson’s disease: A retrospective study
title_full Decreased cerebrospinal fluid orexin levels not associated with clinical sleep disturbance in Parkinson’s disease: A retrospective study
title_fullStr Decreased cerebrospinal fluid orexin levels not associated with clinical sleep disturbance in Parkinson’s disease: A retrospective study
title_full_unstemmed Decreased cerebrospinal fluid orexin levels not associated with clinical sleep disturbance in Parkinson’s disease: A retrospective study
title_short Decreased cerebrospinal fluid orexin levels not associated with clinical sleep disturbance in Parkinson’s disease: A retrospective study
title_sort decreased cerebrospinal fluid orexin levels not associated with clinical sleep disturbance in parkinson’s disease: a retrospective study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803214/
https://www.ncbi.nlm.nih.gov/pubmed/36584130
http://dx.doi.org/10.1371/journal.pone.0279747
work_keys_str_mv AT ogawatakuya decreasedcerebrospinalfluidorexinlevelsnotassociatedwithclinicalsleepdisturbanceinparkinsonsdiseasearetrospectivestudy
AT kajiyamayuta decreasedcerebrospinalfluidorexinlevelsnotassociatedwithclinicalsleepdisturbanceinparkinsonsdiseasearetrospectivestudy
AT ishidohideaki decreasedcerebrospinalfluidorexinlevelsnotassociatedwithclinicalsleepdisturbanceinparkinsonsdiseasearetrospectivestudy
AT chibashigeru decreasedcerebrospinalfluidorexinlevelsnotassociatedwithclinicalsleepdisturbanceinparkinsonsdiseasearetrospectivestudy
AT revankargajanans decreasedcerebrospinalfluidorexinlevelsnotassociatedwithclinicalsleepdisturbanceinparkinsonsdiseasearetrospectivestudy
AT nakanotomohito decreasedcerebrospinalfluidorexinlevelsnotassociatedwithclinicalsleepdisturbanceinparkinsonsdiseasearetrospectivestudy
AT taniguchiseira decreasedcerebrospinalfluidorexinlevelsnotassociatedwithclinicalsleepdisturbanceinparkinsonsdiseasearetrospectivestudy
AT kanbayashitakashi decreasedcerebrospinalfluidorexinlevelsnotassociatedwithclinicalsleepdisturbanceinparkinsonsdiseasearetrospectivestudy
AT ikenakakensuke decreasedcerebrospinalfluidorexinlevelsnotassociatedwithclinicalsleepdisturbanceinparkinsonsdiseasearetrospectivestudy
AT mochizukihideki decreasedcerebrospinalfluidorexinlevelsnotassociatedwithclinicalsleepdisturbanceinparkinsonsdiseasearetrospectivestudy